Cargando…

A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders

It is required that the clinical screening of metabolic disorders in newborns meet International Organization for Standardization 15189-2012 approval. The new tandem mass spectrometry (MS/MS) based screening system and its companion reagent should be independently authenticated before their implemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yulan, Chen, Yao, Qiu, Xiaolong, Chen, Weifen, Lin, Qingying, Zeng, Yinglin, Zhao, Hong, Zhu, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531236/
https://www.ncbi.nlm.nih.gov/pubmed/31083189
http://dx.doi.org/10.1097/MD.0000000000015500
_version_ 1783420792635129856
author Zheng, Yulan
Chen, Yao
Qiu, Xiaolong
Chen, Weifen
Lin, Qingying
Zeng, Yinglin
Zhao, Hong
Zhu, Wenbin
author_facet Zheng, Yulan
Chen, Yao
Qiu, Xiaolong
Chen, Weifen
Lin, Qingying
Zeng, Yinglin
Zhao, Hong
Zhu, Wenbin
author_sort Zheng, Yulan
collection PubMed
description It is required that the clinical screening of metabolic disorders in newborns meet International Organization for Standardization 15189-2012 approval. The new tandem mass spectrometry (MS/MS) based screening system and its companion reagent should be independently authenticated before their implementation in clinical diagnosis laboratories. Linearity, stability, accuracy, and precision evaluations were carried out to verify the performance of the Waters ACQUITY TQD MS/MS system with the NeoBase non-derivatized MS/MS PerkinElmer kit for detecting amino acids and acylcarnitine in newborns with metabolic disorders. Statistically, the correlation coefficient (R(2)) of 0.9982 to 0.9999 indicates good linearity. The measurements at the beginning and end of the reagent storage procedure were taken for stability verification. No significant difference was detected between the 2 periods. The amino acid exhibited a degree of bias in the range of 0% to 14.17%, with acylcarnitine's being was in the range of 0% to 14.84%; they consequently passed the quality assessment requirements for clinical laboratories of the China National Centre. The amino acids’ within-run, between-run, and day-to-day run precision were 1.19% to 7.68%, 1.63% to 5.01%, and 4.77% to 12.48%, respectively, while the total imprecision was 5.55% to 13.33%. Acylcarnitine's within-run, between-run, and day-to-day run precision was 1.2% to 8.43%, 0.19% to 9.60%, and 2.33% to 10.74%, respectively, while it's total imprecision was 6.57% to 13.99%. The manufacturer declared that the total imprecision of the tests, using Multiple Reaction Monitoring, should be less than or equal to 25% of the coefficient of variation for the kit's high and low-quality control levels. The performance of the non-derivatized MS/MS screening system in detecting the amino acids and acylcarnitines passed the test's requirements. It was maintained in accordance with the routine clinical chemical detection system.
format Online
Article
Text
id pubmed-6531236
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-65312362019-06-25 A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders Zheng, Yulan Chen, Yao Qiu, Xiaolong Chen, Weifen Lin, Qingying Zeng, Yinglin Zhao, Hong Zhu, Wenbin Medicine (Baltimore) Research Article It is required that the clinical screening of metabolic disorders in newborns meet International Organization for Standardization 15189-2012 approval. The new tandem mass spectrometry (MS/MS) based screening system and its companion reagent should be independently authenticated before their implementation in clinical diagnosis laboratories. Linearity, stability, accuracy, and precision evaluations were carried out to verify the performance of the Waters ACQUITY TQD MS/MS system with the NeoBase non-derivatized MS/MS PerkinElmer kit for detecting amino acids and acylcarnitine in newborns with metabolic disorders. Statistically, the correlation coefficient (R(2)) of 0.9982 to 0.9999 indicates good linearity. The measurements at the beginning and end of the reagent storage procedure were taken for stability verification. No significant difference was detected between the 2 periods. The amino acid exhibited a degree of bias in the range of 0% to 14.17%, with acylcarnitine's being was in the range of 0% to 14.84%; they consequently passed the quality assessment requirements for clinical laboratories of the China National Centre. The amino acids’ within-run, between-run, and day-to-day run precision were 1.19% to 7.68%, 1.63% to 5.01%, and 4.77% to 12.48%, respectively, while the total imprecision was 5.55% to 13.33%. Acylcarnitine's within-run, between-run, and day-to-day run precision was 1.2% to 8.43%, 0.19% to 9.60%, and 2.33% to 10.74%, respectively, while it's total imprecision was 6.57% to 13.99%. The manufacturer declared that the total imprecision of the tests, using Multiple Reaction Monitoring, should be less than or equal to 25% of the coefficient of variation for the kit's high and low-quality control levels. The performance of the non-derivatized MS/MS screening system in detecting the amino acids and acylcarnitines passed the test's requirements. It was maintained in accordance with the routine clinical chemical detection system. Wolters Kluwer Health 2019-05-13 /pmc/articles/PMC6531236/ /pubmed/31083189 http://dx.doi.org/10.1097/MD.0000000000015500 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Zheng, Yulan
Chen, Yao
Qiu, Xiaolong
Chen, Weifen
Lin, Qingying
Zeng, Yinglin
Zhao, Hong
Zhu, Wenbin
A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders
title A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders
title_full A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders
title_fullStr A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders
title_full_unstemmed A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders
title_short A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders
title_sort verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531236/
https://www.ncbi.nlm.nih.gov/pubmed/31083189
http://dx.doi.org/10.1097/MD.0000000000015500
work_keys_str_mv AT zhengyulan averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT chenyao averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT qiuxiaolong averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT chenweifen averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT linqingying averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT zengyinglin averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT zhaohong averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT zhuwenbin averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT zhengyulan verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT chenyao verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT qiuxiaolong verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT chenweifen verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT linqingying verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT zengyinglin verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT zhaohong verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders
AT zhuwenbin verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders